Moderna Stock Surge Puts These Oncology Biotechs On Retail Investors Radar
Cancer research just stepped into a higher gear, and Moderna is suddenly back in the spotlight after a 14% jump tied to a fresh oncology push. A fast-track NIH campaign using AI and mRNA tools has pulled investor attention toward companies linked to next generation cancer therapies. This piece walks through 3 stocks exposed to that news and helps you judge whether they deserve a closer look or a wider berth right now.
The three stocks that follow are just a small sample pulled from a wider oncology screen. The full filter surfaced 19 more US‑listed cancer focused biotechs and drug developers with similarly detailed backstories that are not covered here.
If you want to identify which candidates best fit your own risk tolerance and thesis, go straight to the Oncology-focused biotech and pharmaceutical stocks screener to compare, analyze, and focus on the oncology exposures that look most compelling to you.
CG Oncology (CGON)
CG Oncology fits directly into this oncology screener theme as a pure-play bladder cancer developer. Its late-stage oncolytic immunotherapy program means the core focus is how far its lead asset can reach if current trial momentum continues.
CG Oncology is a late-stage biopharmaceutical business developing cretostimogene grenadenorepvec, an oncolytic immunotherapy for non muscle invasive bladder cancer. The company is currently generating about $6 million from biotechnology activities in the United States and has a roughly US$5.7b market cap.
Planned expansion of cretostimogene into intermediate risk and BCG exposed NMIBC, supported by the fully enrolled 364 patient PIVOT-006 trial and the planned randomized Phase 3 in roughly 50,000 BCG exposed patients, could materially widen CG Oncology’s treated population and influence future revenue scale.
The key variable for CG Oncology is what happens if one future pricing and access pressure point shifts even slightly against current expectations.
If that single pressure point matters to your thesis, read the full narrative for CG Oncology to see how pricing risk, trial design, and execution could be pulling in opposite directions.
TriSalus Life Sciences (TLSI)
TriSalus Life Sciences plugs neatly into this oncology-focused screen because it is trying to address liver and pancreatic cancer treatment challenges with drug delivery hardware and immunotherapy. The business generated about $45 million from its TriSalus segment in the US and carries a roughly $250 million market cap.
TriSalus Life Sciences provides oncology exposure through devices and drugs rather than headline mRNA or CAR T stories. This can matter when large cancer initiatives draw additional attention to delivery-focused platforms.
Growing use of TriNav across the full radioembolization care pathway, supported by the CMS HCPCS code C8004 that now reimburses both mapping and treatment procedures, increases the number of billable cases per patient and can support higher revenue density per account over time.
One key consideration is how a next phase of that liver-focused rollout might shift the cost and profit balance relative to what many investors currently model.
That shift in the cost and profit mix is exactly what the full narrative for TriSalus Life Sciences unpacks, including where TriSalus Life Sciences’ rollout could be accelerating or quietly stalling next.
Legend Biotech (LEGN)
Legend Biotech fits directly into this oncology-focused screen through its CAR T therapies for multiple myeloma and other cancers, giving you exposure to cell-based treatments that sit close to the NIH push into advanced cancer platforms and to the broader mRNA and AI oncology narrative.
Legend Biotech generates about US$1.3b from biotechnology activities and has a roughly US$3.6b market cap, reflecting a pure oncology cell therapy focus built around cilta cel and a broader CAR T portfolio across blood cancers and solid tumors.
Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by survival data, ongoing clinical trials (CARTITUDE-5 and CARTITUDE-6), and label updates that may increase patient access.
What matters next is how one pressure point around cost, capacity, and partnership economics ultimately shapes the earnings power behind those therapies.
That pressure point is only the starting line, and the full narrative for Legend Biotech shows how Legend Biotech’s capacity, partnerships, and risk profile could be quietly decoupling from simple headline expectations.
Seeking Alternatives Beyond Oncology Ideas
Fresh opportunities move fast as momentum builds, prices shift, and quiet themes gain traction under the radar for now. Scan these curated stock sets before the crowd and act now.
- Spot potential turnarounds in smaller tickers by tracking 14 elite penny stocks with strong financials that pair higher risk with stronger balance sheets and cleaner financials than many typical micro caps.
- Target powerful compounding income streams through 8 dividend fortresses and see which high-yield payers still match solid fundamentals while payout policies remain intact.
- Ride the build out of next generation infrastructure with 43 power grid technology and infrastructure stocks focused on companies tied to grid upgrades, resilience projects, and electrification momentum.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com